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Evidence suggests that users of ecstasy (3,4-methylenedioxymethamphetamine) have 
behavioural and cognitive deficits and show increased impulsivity. Impulse control 
impairments have been shown to be common to a number of addictive behaviours and 
may constitute a risk factor for drug abuse and dependence. The aim of this study was to 
investigate brain activation during response inhibition and performance monitoring in 
current recreational drug users who predominantely used ecstasy. Twenty drug users (ten 
female) and twenty healthy controls were scanned during performance of a response 
inhibition GO/NOGO task using functional magnetic resonance imaging. No performance 
deficits were evident. However, the drug user group revealed elevated frontal and parietal 
BOLD response during successful inhibitions, and temporal, frontal, and cingulate 
hyperactivity during commision errors.  In addition, the users showed reduced 
deactivation in the default-mode network during task performance. Whether contributing 
to or arising from drug use, these results reveal dysregulation in brain regions subserving 
cognitive control and default mode processes in current recreational drug users mirroring 
effects previously observed for “harder” drugs of abuse. 
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Introduction 
Heightened impulsivity is a feature of a number of clinical disorders including 
psychopathy, attention deficit hyperactivity disorder, bulimia nervosa, and drug abuse 
(American Psychiatric Association, 1994). In relation to the regular use of ecstasy (3,4-
methylenedioxymethamphetamine) impulsivity has received particular attention as 
aggressive behaviours (Gerra et al 2000) and serotonergic depletion in animals and 
humans (Mc Cann et al  1994; Hatzidimitriou et al  1999; Reneman et al 2001; Gudelsky 
and Yamamato, 2008) have been associated with both ecstasy use and impulsivity. 
However, the evidence for impulse control impairments in recreational drug users who 
predominantely used ecstasy is inconsistent.  For example, ecstasy users revealed 
elevated impulsivity on the Matching Familiar Figures Test (MFFT) (Morgan et al 1998; 
Morgan et al 2002; Morgan et al 2006; Quednow et al 2007) and on trait impulsivity 
(Morgan et al 1998; Parrott, 2000b; Butler and Montgomery, 2004) in comparison to 
drug-naïve controls. However, there are reports of failures to replicate these deficits on a 
response inhibition GO/NOGO task (Fox et al 2002; Gouzoulis-Mayfrank et al 2003), a 
Stop Signal Test (von Geusau et al 2004), Stroop tests (Dafters, 2006; Vollenweider 
1998), and on trait impulsivity (Clark et al, 2008).  Previous studies also found that 
polydrug users, including users who had or had not used ecstasy, reported similar levels 
of impulsivity (Morgan et al 1998; Tuchtenhagen et al 2000; Daumann et al 2001; 
Morgan et al 2002; Butler and Dafters et al 2004; Hoshi et al 2007a; Hanson et al 2008), 
suggesting that elevated impulsivity may characterise drug users in general and not 
specifically those who have a history of ecstasy use. 
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Impulsivity is a complex and multidimensional psychological construct (Gerbing et al. 
1987; Malle and Neubauer 1991; Moeller et al. 2001). This study opts to study one well-
characterised aspect of impulsivity, response inhibition, given that its neuroanatomy is 
well understood, it is relatively easy to assess, provides robust functional activation 
measures (Garavan et al 1999) and, critically, it captures an aspect of impulsivity that has 
been shown to reveal performance and/or functional differences in previous tests of other 
drug using groups (Kaufman et al 2003; Fu et al 2008). The ability to inhibit prepotent 
behaviours is complemented by performance monitoring functions in that efficient control 
requires cognitive processes to identify when an error has occurred (Kiehl et al 2000; 
Hester et al 2004). Although evidence is inconsistent (Chamberlain and Sahakian, 2007), 
there is a longstanding association between reduced 5-HT (serotonin) neurotransmission 
and behavioural impulsivity (Tye, et al 1977; Soubrié et al 1986; Evenden et al 1999; 
Eagle at al 2009) and impaired monitoring (Risch and Nemeroff, 1992; Beats et al 1996; 
Elliott et al. 1997; Murphy et al. 2003). 
 
The cognitive or neurobiological deficits that can be associated with recreational drug use 
remains unresolved. Even if not as harmful as harder drugs and if less likely to lead to 
dependence (Nutt et al., 2007), recreational use of drugs such as ecstasy and cannabis 
typically occurs at a younger age and by more people so any deleterious effects of these 
drugs, coupled with their possible role as gateway drugs to other harder drugs, may 
represent a significant epidemiological problem. In addition, accumulating evidence 
suggests that some neurocognitive deficits observed in users may pre-exist use (Tarter et 
al 2003; dalley et al 2007; Verdejo-García et al 2008 Thus, observing neurocognitive 
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impairments in non-treatment seeking “recreational” users may give insights into the 
deficits that broadly characterise drug users insofar as there may be certain cognitive 
impairments relevant to all addictions.  
 
The present study sought to investigate the neural basis of response inhibition and 
performance monitoring in current recreational drug users who use ecstasy as their 
primary drug of choice.  An equal number of males and females were tested based on the 
evidence that current ecstasy use in females may lead to greater cognitive vulnerability 
(Topp et al 1999; Lynch et al 2002; Von Gersau et al 2004).  More specifically, using a 
GO/NOGO event-related task we investigated Blood Oxygen Level-Dependent (BOLD) 
activation underlying response inhibition and performance monitoring in current 
recreational drug users who predominantely used ecstasy and healthy controls.  
Performance of GO/NOGO tasks places demands on behavioural inhibition processes, in 
that prepotent responses must be suppressed. Additionally the Impulsiveness 
Venturesomeness and Empathy questionnaire (IVE) was administered to provide a 
supplementary, self-report trait measure of impulsivity. The hypothesis was that 
polysubstance users who predominantely used ecstasy would report elevated measures of 
state and trait impulsivity and reveal dysregulated brain functioning during response 
inhibition and performance monitoring compared to healthy controls. 
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Methods and Materials 
 
Participants 
The drug-using group included 20 current users of ecstasy and the drug-naïve group was 
comprised of 20 participants with no history of illicit drug use. Participants were recruited 
by poster recruitment and by the snowballing method. Participants in the drug-naïve 
group were required to have never used any illicit substance. Participants in the drug-
using group were required to be current users of ecstasy and to have consumed at least 40 
ecstasy tablets over a period of a year, but not necessarily over the immediately preceding 
year. With the exception of cannabis, participants in the drug-using group  were excluded 
if they used any other illicit drugs on more than ten occasions in their lifetime (or more 
than fifteen times if the substance had not been used in the five years that preceded the 
study) and were required to be abstinent of these drugs for a minimum period of 10 weeks 
prior to testing. Participants in both groups were also excluded if they had reported either 
past or present neurological or psychiatric problems. Given the fact that daily smoking of 
cannabis is part of the lifestyle of most club drug users (Daumann et al 2001), ecstasy 
users who were also cannabis users were not excluded from the study or required to 
abstain from smoking cannabis prior to participation. All drug-using participants who 
reported cannabis use (last use 0.5-12 days since last use), with the exception of one 
participant who had reported use three years prior to study participation, tested positive 
for cannabis. Drug users were requested to abstain from ecstasy for at least 48 hours prior 
to study participation. Given this abstinence period, all participants provided a negative 
urine sample for ecstasy. Additional urine analysis screening for methadone, 
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benzodiazepines, cocaine, opiates, barbiturates and tricyclic antidepressants (Cozart 
Rapid Urine, UK) revealed negative results in both groups. All participants gave informed 
consent and the study was approved by the School of Psychology in Trinity College 
Dublin. 
Table 1 shows the group demographics and drug use history for both the drug-using 
group and controls. The groups did not differ significantly in terms of verbal IQ as 
assessed by the National Adult Reading Test (NART), age, gender, years of education, 
alcohol or use of other illicit drugs with the expected exception of ecstasy and cannabis as 
specified in the selection criteria. The drug-using group self-reported higher Beck 
Depression Inventory (BDI) scores.  
 
Experimental design 
 
The GO/NOGO task 
Participants completed a GO/NOGO task previously used for functional imaging of 
cocaine users (Kaufman et al., 2003) in which the letters X and Y were presented serially 
in an alternating pattern at 1 Hz and participants were required to make a button press 
response to each letter. Responses were to be withheld to NOGO stimuli: a NOGO 
occurred when the alternation was interrupted (e.g., the third stimulus in the train X-Y-Y-
X-Y). The event-related design of this experiment allowed the NOGOs to be distributed 
unpredictably throughout the stimulus series. The inter-stimulus interval was 400 ms and 
each stimulus was presented for 600ms. Based on the work of Garavan et al. (2002) these 
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timing parameters were chosen to produce approximately an equal number of successful 
response inhibitions (STOPS) and errors of commission (ERRORS) in each subject. 
Participants were instructed to try to respond while the stimulus was on screen and 
responses and response speed were recorded. Prior to scanning participants completed a 
60 second practice block of the task that contained six NOGO stimuli. During fMRI 
scanning, participants completed two runs that contained 450 GO stimuli and 50 NOGO 
stimuli, resulting in an average interval of ten seconds between NOGOs.  
 
Psychometric measures 
After scanning participants completed the Impulsiveness, Venturesomness and Empathy 
Questionnaire (IVE). The IVE questionnaire contains 54 items requiring yes/no responses 
and consists of three scales assessing impulsiveness, venturesomeness and empathy 
(Eysenck et al 1991). Summary scores for impulsiveness and empathy each range from 0 
to 19 and scores for venturesomeness range from 0 to 16 with higher scores indicating 
higher levels of the trait. Four participants from the ecstasy using group and one 
participant from the control group did not complete the IVE. 
 
 Imaging parameters  
All scanning was conducted on a Philips Intera Achieva 3.0 Tesla MR system (Best, The 
Netherlands) equipped with a coil-mounted mirror that reflected a 640 x 480 pixel 
display, projected on a panel placed behind the subject’s head outside the magnet. 
Imaging started with 31.5 seconds of standard scout images to adjust head positioning, 
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followed by a reference scan to resolve sensitivity variations. Imaging used a parallel 
SENSitivity Encoding (SENSE) approach (Pruessmaan et al. 1999) with reduction factor 
2. 180 high-resolution T1-weighted anatomic MPRAGE axial images (FOV 230 mm, 
thickness 0.9 mm, voxel size 0.9 x 0.9 x 0.9) were then acquired (total duration 6 
minutes), to allow subsequent activation localization and spatial normalization. Thirty-
two non-contiguous (10% gap) 3.5 mm axial slices covering the entire brain were 
collected using a T2* weighted echo-planar imaging sequence (TE = 35 ms, TR = 2000 
ms, FOV 224 mm, 64 x 64 mm matrix size in Fourier space).  
 
Time-series analyses  
The fMRI data were analysed using the AFNI software package (Cox, 1996). Time-series 
data were motion-corrected using 3D volume registration (least-squares alignment of 
three translational and three rotational parameters). Activation outside the brain was 
removed using edge detection algorithms. Deconvolution techniques calculated separate 
event-related haemodynamic response functions at 2s temporal resolution for successful 
response inhibitions (STOPS) and errors of commission (ERRORS). The haemodynamic 
response functions were then modelled voxelwise with a gamma-variate function using 
non-linear regression (Murphy and Garavan ,2005). An area-under-the-curve measure of 
the gamma-variate model was expressed as a percentage of the tonic baseline activity and 
served as the activation measure for the event-related responses. Activation maps were 
warped into a standard stereotaxic space (Talairach et al., 1998) and spatially blurred with 
a 4.2-mm full-width at half-maximum isotropic Gaussian filter after performing a second 
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edge detection on the skull-stripped brain. ERROR and STOP activation maps for both 
the drug-using group and drug-naïve controls were determined with one-sample t-tests 
against the null hypothesis of zero activation changes (i.e., no change relative to tonic 
task-related activity (p ≤ 0.001).   In addition, voxelwise independent-samples t-tests 
comparing drug users and drug-naïve controls were performed separately for both 
ERROR and STOP activations. Significant voxels passed a voxelwise statistical threshold 
(t(1,38)= 8.94, P ≤ 0.005) and were required to be part of a larger 286 µl cluster of 
contiguous significant voxels. Cluster-sizes for both the one-sample and the between-
group t-tests were determined through Monte Carlo simulations and resulted in a 5% 
probability of a cluster surviving due to chance.  
 
Statistical analysis 
Behavioural data were analyzed with the statistical package SPSS (version 12). 
Independent-group t-tests tested for group differences on self-reported psychometric 
measures and GO/NOGO performance measures. All tests were two-tailed and criterion 
for significance was set at p≤ 0.05. To conduct an analysis of covariance (with BDI 
scores as the covariate), mean activation was calculated for each participant for the 
functionally-defined regions-of-interest identified by the between-group voxelwise 
contrasts.  Separate ANCOVAs were performed for each region. In addition, separate 2 
(group) x 2 (gender) ANCOVAs (with BDI scores as the covariate) were also conducted 
on self-reported psychometric measures, GO/NOGO performance measures, and on these 
region-of-interest activation measures. Within the drug-using group, Pearsons correlations 
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investigated relationships between behavioural performance, ecstasy use and brain 
activation. 
 
Results 
 
Behavioural results 
Independent-group t-tests revealed that the groups did not differ on the impulsivity (p ≤ 
0.5), venturesomeness (p ≤  0.4), and empathy (p ≤  0.6) scales of the IVE nor did they 
differ on any GO/NOGO performance measures including % STOPs (p ≤  0.5), error of 
commission reaction times (p ≤  0.6), or GO reaction times (p ≤  0.3) (Table 2). No 
gender differences or gender x group interactions were observed for any of these 
measures. 
 
Neuroimaging results 
Separate task activation maps for each group are shown in Figure 1. For STOPS, 
prominent activation was observed in the right inferior frontal gyrus and, to lesser extents,  
dorsolateral and ventrolateral PFC and right parietal cortex. ERRORS exhibited robust 
activation in bilateral ACC, bilateral PFC, bilateral insula, bilateral temporal cortex, and 
right parietal cortex. Qualitatively, the activation patterns of the drug-using group 
appeared similar but larger than the controls.  In confirmation of this pattern, group 
differences for STOPS from the voxelwise independent-groups t-tests were found in the 
right middle and inferior frontal gyri (centre-of-mass: 41, 33, 18), right middle frontal 
gyrus (45, 12, 34), and right inferior parietal lobule  (42, -40, 45). In these areas, 
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activation was greater for drug-users.  Similarly, greater ERROR activations in the users 
were evident in the right middle and inferior temporal gyri (53, -41, -10). On ERROR 
trials, controls showed significantly greater deactivation in the left medial frontal gyrus 
(0, 61, 1) and left posterior cingulate (-1, -47, 26) (see Figure 2 and Table 3). All 
significant group differences persisted even with the addition of the BDI covariate. In 
addition, no gender differences and no gender x group effects were found. 
 
In the drug-using group, high frequency (number of times of ecstasy use) (r = 0.48, 
p≤0.05) and high consumption (number of ecstasy tablets) (r = 0.46, p≤0.05) in the month 
prior to testing correlated with activation in the posterior cingulate ERROR cluster. The 
positive correlations indicate that in these regions, which were deactivated in controls, 
there were smaller levels of deactivation (in fact, for many users, small levels of positive 
activation) in those users who had higher levels of recent use. Neither impulsivity from 
the IVE, behavioural performance from the GO/NOGO task, nor any drug use measure 
correlated with activation in any of the brain regions that revealed a group difference. 
Also impulsivity from the IVE did not correlate with behavioural performance from the 
GO/NOGO task.  
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Discussion 
 
Successful response inhibition recruited the right fronto-parietal cortex, whereas error 
processing was associated with bilateral frontal, bilateral insula and anterior cingulate 
activity, consistent with previous results obtained using response inhibition tasks (Braver 
et al 2001; Menon et al 2001; Garavan et al 2002; Aron and Poldrack, 2006). The results 
of this study show that in the absence of performance deficits, current recreational drug 
users whose predominant drug of choice was ecstasy, demonstrate hyperactive brain 
function for both successful and unsuccessful inhibitions relative to well-matched 
controls.  The lack of impairment in the ecstasy using group on GO/NOGO task 
performance is in agreement with other studies (Fox et al 2002; Gouzoulis-Mayfrank, et 
al 2003). Indeed, for brain imaging purposes the absence of performance differences can 
be advantageous enabling us to discount secondary performance-related effects (e.g., 
frustration) from confounding the group comparison (Murphy and Garavan, 2004). 
Instead, the hyperactivity of the drug users in the absence of performance differences 
indicates that inhibiting was more demanding requiring greater levels of neuronal 
involvement.  The ability of the users to marshall additional resources to maintain levels 
of performance comparable to the controls may explain why previous studies have failed 
to detect impairment in inhibitory control in ecstasy users and suggests that their 
functional impairment is more subtle than seen, for example, with the same task in 
cocaine users (Kaufman et al., 2003).  That said, another consideration is that our drug-
using group may have been a particularly high-functioning group (note that estimated IQ 
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was well above average) so the evidence here of brain activation differences during 
cognitive control may still be noteworthy.  With regards to trait impulsivity, no 
differences were observed between the drug-using group and controls on the IVE 
measures, a result that is consistent with some previous studies (Clark et al 2008) but not 
with others (Morgan et al., 1998; Parrott et al., 2000). The cause for these discrepant 
findings are uncertain and may reflect differences in sample-specific characteristics. 
Despite previous reports that females are particularly vulnerable to the deleterious effects 
of current ecstasy use (Topp et al 1999; Lynch et al 2002; von Gersau et al 2004) the 
present results revealed no effect of sex on the differences in brain function between the 
drug users and controls. 
 
The drug-using group demonstrated hyperactive neural responses for STOPs in the right 
dorsolateral PFC (DLPFC), inferior frontal gyrus (IFG) and parietal lobule. A widespread 
network of brain regions is involved in response inhibition but the network of right 
prefrontal (especially right inferior frontal gyrus) and inferior parietal regions are thought  
central to response inhibition (Garavan et al 1999; Konishi et al 1999; Liddle et al 2001, 
Garavan et al 2002, Hester and Garavan, 2004; Chambers et al 2006; Li et al 2006b).  The 
magnitude of activity in this network may reflect the demands a successful inhibition 
places on an individual. Consistent with this interpretation, Garavan et al. (2006) showed 
greater fronto-parietal activation in more absentminded healthy participants, Braet et al. 
(2009) showed greater fronto-parietal activation in adolescents relative to adults and 
Nielson et al. (2002) showed greater left prefrontal activation in older patients; in these 
studies, which used very similar tasks to the one used in this experiment, the between-
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group activation differences in the absence of performance differences, were interpreted 
to reflect greater task difficulty. Therefore, the observation of ecstasy-related 
hyperactivity in this response-inhibition network in the absence of performance 
differences can plausibly be interpreted to indicate that greater demands were placed on 
this system in the users to maintain performance at levels comparable to the non-using 
controls.  
 
Consistent with the frontal hyperactivity reported here, a previous fMRI study found that 
ecstasy users showed greater activation in PFC compared with non-drug-using controls 
during performance of an immediate and delayed working memory task (Moeller et al 
2004). The present results may be partly related to a substantial body of work associating 
ecstasy with serotonergic frontal deficits (O’Hearn et al 1988; Wilson et al 1989; Fischer 
et al 1995; Hatzidimitriou et al 1999). Although at a conceptual level the 5-HT theory of 
impulsivity may represent an over-simplification (Clark et al 2008), altered 5-HT 
neurotransmission in the PFC has been associated with failures of inhibitory control 
(Leyton et al 2001; Clarke et al 2004; Liu et al 2004) with recent evidence implicating 5-
HT in being able to wait to respond rather than being able to countermand a response that 
has already begun (Eagle et al., 2009). However, the current study contained no 
assessment of neurotransmitter levels and it is noteworthy that there is evidence 
suggesting that noradrenaline rather than 5-HT may be the key neurotransmitter 
underlying motor inhibition (Chamberlain and Sahakian, 2007). 
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During ERRORS the drug-using group demonstrated hyperactive neural responses in the 
left medial frontal gyrus, right middle temporal gyrus and left posterior cingulate and 
there were positive correlations between the posterior cingulate area and measures of 
ecstasy use.  Notably, the users did not differ in the areas that are most often linked with 
error-related processes such as the anterior cingulate and insula (Hester et al 2004; Lerner 
et al 2009) and which have been associated with dopamine function (Cropley et al 2006;; 
Klein et al 2007; Jochman and Ullsperger 2008). As both the medial PFC and posterior 
cingulate are part of the default-mode network (regions that are typically deactivated 
during active task performance; Greicius et al., 2003), the reduced deactivation in these 
regions in users in contrast to controls suggests an impairment in users in turning off the 
default mode on their failed attempts to inhibit. Impaired performance on attention 
demanding tasks has previously been associated with failure to deactivate the default-
mode circuitry in both normal and clinical groups (Lawrence et al 2003; Mc Kieran et al 
2003; Buckner et al., 2008). There is also a growing literature implicating the PCC in 
addiction, specifically with regard to craving and it being a predictor of relapse (Brody et 
al., 2007; Egan et al., 2003; Franklin et al., 2007; Paulus et al., 2005; Small et al., 2001). 
The exact functional or psychological consequences of dysregulation in the PCC are 
unclear but it is possible that the self-referential processes thought to be subserved by the 
PCC that are heightened during craving may contribute background noise during 
cognitive task performance.  Indeed, it is tempting to speculate, given the absence of 
group differences in performance, that this region may be a particularly sensitive marker 
of drug-related dysfunction.  
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Low correlations between self-report and behavioural measures of impulsivity are a 
common finding (Gerbing et al 1987; Morgan et al 1998; Wingrove and Bond 1998; 
Lijffijt et al 2004; 2004; Reynolds, et al 2006; Douglas, et al 2007). As we failed to find 
associations between response inhibition performance, brain activation and trait 
impulsivity, our results are consistent with the view that impulsivity is not a single 
construct, but is composed of multiple traits and dispositions that may be somewhat 
independent (e.g. Gerbling et al. 1987). Moreover, whereas questionnaire ratings indicate 
general behavioural tendencies across a range of situations and rely on a subjective 
evaluation of one’s behaviour, laboratory tasks provide an objective measure of a specific 
component of impulsivity at a single point in time.  
 
It should be noted that rather than testing abstinent users in whom persistent neurotoxic 
effects of ecstasy might be evaluated, the present assessment is of recreational drug users 
who primarily use ecstasy and who have differing periods of abstinence from ecstasy and 
other illicit drugs. A notable characteristic of this sample is that a large proportion of 
ecstasy participants tested positive for cannabis and some had also used ecstasy within 
two-three days prior to fMRI scanning. Negative subacute effects of MDMA on cognition 
and mood have been previously characterized  (Parrott and Lasky, 1998). Amphetamines 
have been reported to cause toxicity (Berman et al., 2009) and some of the participants 
also used amphetamines up to a total of 15 times in their lifetime. A larger proportion of 
the drug users were nicotine smokers. We did not record if participants smoked nicotine 
on the day of testing but as participants were not requested to abstain from nicotine prior 
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to testing the potential influence of nicotine as a confounding factor cannot be 
eliminated.  Consequenty, the current results might best be interpreted as showing the 
neurocognitive functioning of current polydrug users, albeit users who primarily use 
ecstasy and cannabis, rather than necessarily demonstrating persistent neurotoxic effects 
of those drugs. Assessing the neurocognitive functioning of current users is of importance 
to understanding how drug use (moreover, the polydrug use that is representative of drug 
users) impacts on the daily functioning and decision making of users. 
 
As these current polydrug users were recruited based on their ongoing regular use of 
ecstasy, it is plausible that ecstasy use or ecstasy use in combination with other drug use, 
may be the cause of the observed brain function dysregulation. Furthermore, although we 
have some evidence that the functional differences observed are related to current ecstasy 
consumption, we can not determine if current effects are attributed to ecstasy use or 
ecstasy use in combination with other drug use. Equally plausible, given the correlational 
nature of research on human drug users, is that these neural effects preceded drug use and 
may have placed individuals at risk for drug use.  Impulsivity is a risk factor for drug use 
(Tarter et al 2003) and compromised monitoring of one’s behaviour may also contribute 
to drug use (Garavan & Stout 2005; Hester et al 2009).  Despite the evidence for impulse 
control deficits in regular ecstasy users being inconsistent, whether contributing to or 
arising from drug use, the present results provide evidence that recreational drug users 
who predominantely used ecstasy display dysregulation in brain regions subserving 
cognitive control and default mode processes, some of which echo observations in users 
dependent on drugs considered more addictive and damaging to health (Nutt et al., 2007) 
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Figure 1. Sagittal sections showing regions activated for successful inhibitions 
(STOPS) and errors of commission (ERRORS) in the GO/NOGO task.  
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Figure 2. STOP and ERROR related brain activation for GO/NOGO task. 
 
 
  
Significantly greater STOP-related activation in the drug-using group relative to controls was observed 
in the right middle and inferior frontal gyrus, right middle frontal gyrus, and right inferior parietal 
lobule. The drug-using group showed greater activation in the left medial frontal gyrus, right middle and 
inferior temporal gyrus, left posterior cingulate for ERRORS. 
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Table 1. Mean and SEM for ecstasy and control groups on demographics and drug 
use history.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*= p < 0.05 control versus ecstasy using group. # = on the day of testing one participant from the control 
group reported using 1 line of cocaine on 4 occasions (last use was 2 years prior to testing and when this 
participant was removed from the analysis the results remained unmodified). The only hallucinogen 
reported was LSD. Means are based on only those subjects reporting non-zero values for certain drug use.  
In these instances, the numbers of subjects reporting any use are given in parentheses. 
 
 Ecstasy Controls 
 (n=20) (n=20) 
   
Age 22.4±0.7 22.5±0.6 
Years of education 15.8±0.5 16.9±0.6 
Verbal intelligence score (NART) 122.1±1.1 123.3±0.9 
Beck Depression Inventory II score 5.8±0.9 3.2±0.7* 
Females/males 10/10 10/10 
Ecstasy use in the last month (no. times) 2.3±0.4 0 
Pills in last month (number) 10.7±2.7 0 
Last ecstasy use (days) 16.17±2.5 0 
Lifetime pills (number) 406.5±88.1 0 
Pills in last year (number) 109.7±29.2 0 
Years of cannabis use 6.8±0.7 (n=15) 0 
Days of use in last month (number) 16.1±2.8 (n=15) 0 
Joints in last month (number) 43.2±12.4 (n=15) 0 
Last cannabis use (days) 102.5±99.1 (n=15) 0 
Lifetime joints (number) 2479±732.1 (n=15) 0 
Years of alcohol use 7.6±0.7 6.32±0.6 
Alcohol use in the last month (no. days) 9.0±1.7 6.1±0.9 
Average units of alcohol per week 14.4±2.1 10.6±0.9 
Years of nicotine use 5.0±0.7 (n=14) 5.3±1.2(n= 6) 
Years of amphetamine use 3.1±0.8 (n=11) 0 
Last amphetamine use (days) 362.1±145.2 (n=11) 0 
Amphetamine use (no. times) 6.3±1.7 (n=11) 0 
Years of cocaine use 3.0±0.4 (n=17) # 
Last cocaine use (days) 152.3±55.4 (n=17) 0 
Cocaine use (no. times) 9.8±1.2 (n=17) 0 
Years of hallucinogen use 1.4±0.8 (n=7) 0 
Last  hallucinogen  use (days) 640.7±264.2 (n=7) 0 
Hallucinogenic use (no. times) 2.2±0.4 (n=7) 0 
Ecstasy use in the last month (no. times) 2.3±0.4 0 
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Table 2. Psychometric and GO/NOGO response inhibition behavioural results. 
 
 
 Ecstasy Control 
IVE   (n=16) (n=19) 
Impulsivity 63±1 64±1 
Venturesomeness 20±1 19±1 
Empathy 24±1 23±1 
   
GO/NOGO performance  (n=20) (n=20) 
% NOGO 52 ± 2 57± 2 
EOC reaction times (ms) 303 ± 8 287 ± 6 
GO reaction times (ms) 323 ± 10 308 ± 8 
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Table 3. Cerebral Foci for GO/NOGO group differences in activation.  
 
centre of mass
Structure Brodmann area Hemisphere Volume (µl) X Y Z
      
STOPS
 
Middle and inferior frontal gyrus 46,10 R 1101 41 33 18
Middle frontal gyrus 9,8,6 R 488 45 12 34
Inferior parietal lobule 40 R 412 42 -40 45
  ERRORS    
Medial frontal gyrus 10 L 723 0 61 1
Middle temporal gyrus 20,37 R 406 53 -41 -10
Posterior cingulate 31, 23, 30 L 331 -1 -47 26
 
 
 
 
